Eli Lilly and Company — deep review (Indianapolis, Marion County, IN)
TL;DR
- Indianapolis-based Lilly is one of the world’s largest pharmaceutical companies; its insulin franchise has been the subject of more than two decades of consumer-pricing complaints, congressional scrutiny, and class actions.
- In March 2023 Lilly announced a 70% price cut on its most-prescribed insulins and capped out-of-pocket cost at $35/month after sustained public pressure — a real, documented improvement.
- Outside insulin, Lilly’s product-safety record is mixed: federal courts have approved billion-dollar settlements (Zyprexa, $1.42B in 2009 over off-label marketing) and the company has settled multiple FCA cases; weight-loss drugs Mounjaro/Zepbound have been the subject of FDA-flagged compounding-pharmacy controversies.
1. What they do
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical manufacturer headquartered at Lilly Corporate Center in downtown Indianapolis. Founded 1876 by Civil War veteran Col. Eli Lilly. Major franchises: diabetes (Humalog, Trulicity, Mounjaro), oncology (Verzenio), neuroscience (Zyprexa historically; donanemab/Kisunla for Alzheimer’s), and obesity (Zepbound, launched late 2023). Per Lilly’s 2024 Annual Report, the company had ~47,000 employees and $45.04 billion in 2024 revenue.
2. What customers actually report
- Insulin pricing — the largest customer-facing complaint pattern. Patients and the American Diabetes Association have documented list-price increases for Humalog of more than 1,200% from 1996 ($21/vial) to 2017 (~$275/vial). The 2019 House Oversight Committee hearing on insulin pricing put Lilly CEO David Ricks under direct questioning about the gap between list and net prices.
- Mounjaro / Zepbound supply — through 2023–2024, FDA listed both as on the official drug-shortage list. Patients reported rationing doses and switching to compounding pharmacies; Lilly sued several compounders alleging unsafe knockoffs (cases publicly filed in Texas and other federal districts in 2024).
- Zyprexa marketing — settled with DOJ in 2009 for $1.415 billion (criminal $515M + civil $800M) over off-label promotion for elderly dementia patients, then the largest individual-corporate criminal fine in U.S. history at the time.
- Positive customer signals — Lilly’s patient assistance program (Lilly Cares) has documented multi-year continuous operation; 2023 $35 insulin cap is verifiable on lilly.com/insulin and was confirmed by independent reporting (NYT, WSJ, AP).
3. What the data shows
- BBB profile (Indianapolis HQ): Eli Lilly & Co. is BBB-accredited; complaint volume on consumer-facing channels is small relative to company size because most disputes route through doctors, insurers, and PBMs.
- Glassdoor: overall employee rating ~3.9–4.1 / 5 across recent years, above pharma-industry median.
- SEC 10-K (2024): $45.04B revenue, $10.59B net income; R&D spend $10.99B (24% of revenue). Capital investment in Indiana: Lebanon LEAP campus announced 2022, $9B+ committed by 2024.
- Federal litigation history: DOJ press release 2009 (Zyprexa); multiple class-action insulin-pricing suits filed 2017–2023 in NJ federal court.
4. How they handle complaints
Lilly maintains a corporate compliance line and a published patient assistance program. Resolution of pricing disputes is typically routed through PBM rebates and patient-assistance pathways rather than consumer-direct refunds, which makes the response less visible than at a consumer-retail company. The 2023 insulin price cuts — while responsive to political and public pressure rather than a complaint process — are an unusually concrete corporate response and are documented in Lilly’s own SEC filings.
5. IBE Score: 6/10 — reasoning
Strong financial and R&D fundamentals; demonstrable corrective action on insulin pricing; offset by a long history of pricing-related complaints, the Zyprexa settlement, and ongoing FDA shortage / compounding-pharmacy disputes around GLP-1 drugs. 6/10 reflects a well-run institution with documented past misconduct and unresolved consumer-pricing tension.
6. Verified public sources
- Eli Lilly 2024 Annual Report (10-K)
- U.S. House Oversight Committee — insulin pricing hearing (April 2019)
- DOJ press release — Eli Lilly Zyprexa $1.415B settlement (Jan 2009)
- FDA Drug Shortages list (Mounjaro / Zepbound 2023–2024)
- Lilly insulin price-cut announcement (March 2023)
- BBB profile — Eli Lilly and Company
7. What this review is, and what it isn’t
- Independent. No payment, sponsorship, or advertising relationship between IBE and the reviewed business.
- Public-record only. Every claim above traces to a source listed in section 6. Where data couldn’t be verified, the review either omits the claim or labels it as a pattern reported by customers (not a finding).
- Not legal or medical advice. If a specific transaction went wrong, document it in writing, escalate to the company first, then to the relevant regulator (Indiana AG, IDOI, IURC, CFPB, FDA, NHTSA, etc.) as appropriate.
- Updated as evidence comes in. If you have a primary-source document that changes any claim above — a court filing, a regulatory order, a settlement agreement — submit it via the tip form. Reviews are revised when verifiable evidence warrants.
This review reflects publicly available information as of the review date listed above. IBE has no commercial relationship with Eli Lilly and Company or its parent entities.